ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

ravulizumab

Also written as “Ravulizumab”, “ALXN1210” and “ALXN1210 SC”.

Its studies are mostly in Hemoglobinuria, Paroxysmal · Myasthenia Gravis · Thrombotic Microangiopathies · Neuromyelitis Optica · Atypical Hemolytic Uremic Syndrome, led by 2 companies.

Drug pageRavulizumab: every studyAll 39 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Mar 23, 202035 company-led studies, 9 open or runningNext primary completion: Jun 25, 2027 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZenecaits history only349 open or runningphase 4since Mar 23, 2020Nov 2, 2015Jun 25, 2027phase 4 · NCT07308574
Regeneron Pharmaceuticals10 open or runningphase 3since Nov 12, 2021Nov 12, 2021none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Regeneron Pharmaceuticals only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Jun 9, 2017Named ravulizumabINNProposed as its International Nonproprietary Name in WHO's List 117 · before, ALXN1210
  2. Nov 12, 2021First study: phase 3 study in Hemoglobinuria, ParoxysmalFirst studyNCT05131204 · 3 enrolled · United States

TargetBeta

C5 →read by rule
“Complement C5 inhibitor”ChEMBL 37, by rule

Other programs on C5

ProgramCompanyFurthest phaseStudies
eculizumabruleAstraZenecaphase 438
pozelimabruleRegeneron Pharmaceuticalsphase 414
zilucoplanruleUCBphase 314
vilobelimabruleinflarx-gmbhphase 313
CrovalimabruleHoffmann-La Rochephase 310
cemdisiranruleRegeneron Pharmaceuticalsphase 310
ABBV-6628AbbViephase 21

Studies

The one study Regeneron Pharmaceuticals leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05131204Hemoglobinuria, Paroxysmal · United States3TerminatedJul 12, 20233

How it is read

Names in the registry

  • “Ravulizumab”, 30 entries
  • “ALXN1210”, 4 entries
  • “ALXN1210 SC”, 1 entry
  • “ALXN1210 IV”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.